Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection ...
Antibody's outside-in signaling shows a route into cancer cells
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...
The Scientist1d
How Does the Gut Immune System Distinguish Between Friends and Foes?
Cell-cell interactions help drive tolerogenic or inflammatory responses to the maelstrom of antigens passing through the gut.
Science Daily1d
Computer model helps identify cancer-fighting immune cells key to immunotherapy
Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.
BioNTech SE: BioNTech Completes Acquisition of Biotheus
Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...
Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery
Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced ...
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...